Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 17/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622627 | 0.94 | HSD11B1 (0.51) | FFAR1FFAR4HSD11B1 | |
| Trifluoroacetic Acid SCHEMBL1024882 | 0.87 | HTR3E (0.51) | FFAR4HSD11B1 | |
| SCHEMBL1025550 | 0.82 | FFAR1 (0.44) | FFAR1FFAR4HSD11B1DPP4DPP9 | |
| Trifluoroacetic Acid SCHEMBL1024329 | 0.81 | ALDH1A1 (0.55) | FFAR1FFAR4DPP4DPP9DPP7 | |
| SCHEMBL25959049 | 0.79 | HSD11B1 (0.52) | FFAR4HSD11B1 | |
| Trifluoroacetic Acid SCHEMBL1026901 | 0.79 | FFAR4 (0.51) | FFAR4 | |
| SCHEMBL13622625 | 0.78 | HTR3E (0.58) | FFAR4HSD11B1 | |
| SCHEMBL23346911 | 0.78 | DRD2 (0.43) | FFAR1 | |
| Trifluoroacetic Acid SCHEMBL1024921 | 0.78 | FFAR4 (0.56) | FFAR1FFAR4DPP4DPP9DPP7 | |
| SCHEMBL23346986 | 0.77 | PDE10A (0.47) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | FFAR1 1611/4885FFAR4 2075/4885HSD11B1 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.